SCHEMBL6183699

SCHEMBL6183699

COc1cc(C=O)cc(NC(=O)OC(C)(C)C)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.41
SCN9A Q15858 1/20 0.37
KDM4E B2RXH2 2/20 0.37
ATR Q13535 1/20 0.37
ALDH1A1 P00352 3/20 0.36
GSK3B P49841 1/20 0.36
DYRK1A Q13627 1/20 0.36
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
TP53 P04637 1/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ADORA3 P0DMS8 2/20 0.34
CYP17A1 P05093 1/20 0.34
CA1 P00915 2/20 0.34
CA2 P00918 1/20 0.34
ADORA1 P30542 1/20 0.34
GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29955278 0.86 ATR (0.44) SCN9AKDM4EATRGSK3BDYRK1A
SCHEMBL1943232 0.83 SCN9A (0.38) SCN9AATRGSK3BDYRK1ACYP17A1
SCHEMBL6180772 0.81 ALDH1A1 (0.45) CYP1A2KDM4EALDH1A1NPC1RAB9A
SCHEMBL31663334 0.80 CYP1A2 (0.45) CYP1A2SCN9AKDM4EATRALDH1A1
SCHEMBL24343974 0.78 CYP1A2 (0.62) CYP1A2KDM4EATRALDH1A1GSK3B
SCHEMBL1258539 0.75 ATR (0.47) ATRGSK3BDYRK1ARAB9ACYP17A1
SCHEMBL22213871 0.75 AAK1 (0.38) SCN9AKDM4EATRGSK3BDYRK1A
SCHEMBL29436150 0.75 AAK1 (0.38) SCN9AKDM4EATRGSK3BDYRK1A
SCHEMBL28458230 0.74 ATR (0.40) CYP1A2SCN9AATRGSK3BDYRK1A
SCHEMBL28997343 0.74 SORT1 (0.48) NPC1RAB9ALCKHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1218376-B1 TYROSINE KINASE INHIBITORS MERCK & CO INC (US) 2005-11-09 EP disclosed
US-6586424-B2 Anticancer agents; anticholesterol agents MERCK & CO., INC. 2003-07-01 US disclosed
US-6586423-B2 2-(Pyridin-2-ylamino)-thiazole-5-carbonitrile derivatives; angiogenesis inhibitors; antitumor and anticarcinogenic agents; atherosclerosis, macular degeneration, diabetic retinopathy MERCK & CO., INC. 2003-07-01 US disclosed
US-20030064996-A1 Tyrosine kinase inhibitors MERCK SHARP & DOHME CORP. 2003-04-03 US disclosed
US-20020147203-A1 Tyrosine kinase inhibitors MERCK & CO., INC. 2002-10-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020147203-A1 Tyrosine kinase inhibitors ERBB2, TYRO3, TIE1 CYP1A2 4812/4885SCN9A 4740/4885KDM4E 2200/4885
US-20030064996-A1 Tyrosine kinase inhibitors ERBB2, TYRO3, TIE1 CYP1A2 4812/4885SCN9A 4740/4885KDM4E 2200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.